These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 33569431)

  • 21. Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
    Moufarrij S; Gazzo A; Rana S; Selenica P; Abu-Rustum NR; Ellenson LH; Liu YL; Weigelt B; Momeni-Boroujeni A
    Gynecol Oncol; 2024 Dec; 191():1-9. PubMed ID: 39276497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Molecular Characterization of
    Garmezy B; Gheeya J; Lin HY; Huang Y; Kim T; Jiang X; Thein KZ; Pilié PG; Zeineddine F; Wang W; Shaw KR; Rodon J; Shen JP; Yuan Y; Meric-Bernstam F; Chen K; Yap TA
    JCO Precis Oncol; 2022 Feb; 6():e2100267. PubMed ID: 35108036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer.
    Zhou Z; Li K; Wei Q; Chen L; Shuai Y; Wang Y; He K; Si L; Zhong Y; Lu J
    J Gastrointest Oncol; 2021 Dec; 12(6):2775-2787. PubMed ID: 35070406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
    Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
    Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.
    Dong S; Zakaria H; Hsiehchen D
    Oncologist; 2022 Mar; 27(3):159-162. PubMed ID: 35274726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families.
    Weber CAM; Krönke N; Volk V; Auber B; Förster A; Trost D; Geffers R; Esmaeilzadeh M; Lalk M; Nabavi A; Samii A; Krauss JK; Feuerhake F; Hartmann C; Wiese B; Brand F; Weber RG
    Acta Neuropathol Commun; 2023 Nov; 11(1):184. PubMed ID: 37990341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors.
    Song Y; Huang J; Liang D; Hu Y; Mao B; Li Q; Sun H; Yang Y; Zhang J; Zhang H; Chen H; Liu H; Zhang S
    Front Oncol; 2020; 10():549777. PubMed ID: 33680909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of
    Sharma MR; Auman JT; Patel NM; Grilley-Olson JE; Zhao X; Moschos SJ; Parker JS; Yin X; Hayward MC; Polite BN; Marangon E; Posocco B; Toffoli G; Hayes DN; Innocenti F
    JCO Precis Oncol; 2017; 2017():. PubMed ID: 30009279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.
    Vauchier C; Pluvy J; Theou-Anton N; Soussi G; Poté N; Brosseau S; Gounant V; Zalcman G
    Lung Cancer; 2021 Oct; 160():28-31. PubMed ID: 34371300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
    Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
    Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.
    Jansen AM; van Wezel T; van den Akker BE; Ventayol Garcia M; Ruano D; Tops CM; Wagner A; Letteboer TG; Gómez-García EB; Devilee P; Wijnen JT; Hes FJ; Morreau H
    Eur J Hum Genet; 2016 Jul; 24(7):1089-92. PubMed ID: 26648449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
    Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
    Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.
    Valle L; Hernández-Illán E; Bellido F; Aiza G; Castillejo A; Castillejo MI; Navarro M; Seguí N; Vargas G; Guarinos C; Juarez M; Sanjuán X; Iglesias S; Alenda C; Egoavil C; Segura Á; Juan MJ; Rodriguez-Soler M; Brunet J; González S; Jover R; Lázaro C; Capellá G; Pineda M; Soto JL; Blanco I
    Hum Mol Genet; 2014 Jul; 23(13):3506-12. PubMed ID: 24501277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
    Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
    Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients.
    Zhu C; Zhu L; Gu Y; Liu P; Tong X; Wu G; Zhu W; Shen W; Bao H; Ma X; Yu R; Wu X; Zhu D; Shu Y; Feng J
    Front Genet; 2021; 12():608742. PubMed ID: 34594355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
    Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
    Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.